Skip to content

Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents

Depression in Adolescence

This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=452) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or GLAD-PC guided prescribing (control intervention).

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    12 to 17

Participation Criteria

Inclusion Criteria:

* Age 12-17
* Depression as the primary concern, confirmed by the treating physician
* QIDS-A17 score greater than or equal to 11 indicating moderate-to-severe symptoms
* Intention to start a new SSRI
* English fluency

Exclusion Criteria:

* Co-occurring psychosis, bipolar disorder, eating disorder, autism spectrum disorder, fetal alcohol spectrum disorder, or intellectual disability
* A score of 2 or 3 on suicide item 13 of the QIDS-A17
* High-risk alcohol or substance use (excluding cannabis and tobacco) as indicated by a score of monthly or more on the S2BI
* History of non-response to 3 or more SSRI medications as confirmed by the treating physician
* Brain stimulation-based therapy initiated within 8 weeks of referral, or plans to initiate/change brain stimulation during study participation
* History of liver or hematopoietic cell transplant
* History of CYP2B6, CYP2C19, or CYP2D6 testing

Study Location

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Backup Contact

Chad Bousman

Primary Contact

Laina McAusland, MSc

[email protected]
Backup Contact

Amanda Newton

Study Sponsored By
University of Calgary
Participants Required
More Information
Study ID: NCT05965401